The patent specifically claims the Form A polymorph of OPT-80, as well as all dosage forms and pharmaceutical compositions including the Form A polymorph of OPT-80. OPT-80 is currently in two Phase III clinical trials for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile-associated disease, or CDAD.
According to Optimer, OPT-80 is a first in-class narrow spectrum antimicrobial agent with excellent activity against many clostridia including Clostridium difficile and moderate activity against certain gram-positive bacteria.
Michael Chang, president and CEO of Optimer, said: “Our scientists have determined that polymorphic Form A is the most stable crystalline form of OPT-80. We believe this patent, along with additional pending patent applications, will enhance our intellectual property protection for OPT-80.”